

# Recurrent hemolytic uremic syndrome caused by *DGKE* gene mutation: a case report

Baek Sup Shin<sup>1</sup> , Yo Han Ahn<sup>1,2,3</sup> , Hee Gyung Kang<sup>1,2,3,4</sup> 

<sup>1</sup>Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Republic of Korea

<sup>2</sup>Department of Pediatrics, Seoul National University College of Medicine, Seoul, Republic of Korea

<sup>3</sup>Kidney Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea

<sup>4</sup>Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury without any association with preceding diarrhea. Dysregulation of the complement system is the most common cause of aHUS, and monoclonal humanized anti-C5 antibodies are now recommended as the first-line treatment for aHUS. However, if the complement pathway is not the cause of aHUS, C5 inhibitors are ineffective. In this study, we report the second reported case of aHUS caused by *DGKE* mutations in Republic of Korea. The patient was an 11-month-old infant who presented with prodromal diarrhea similar to typical HUS, self-remitted with conservative management unlike complement-mediated aHUS but recurred with fever. While infantile aHUS often implies genetic dysregulation of the complement system, other rare genetic causes, such as *DGKE* mutation, need to be considered before deciding long-term treatment with C5 inhibitors.

**Keywords:** Atypical hemolytic uremic syndrome; Complement factor H; DGK epsilon; Eculizumab; Thrombotic microangiopathies

## Introduction

Hemolytic uremic syndrome (HUS) is a form of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury [1]. In children, enterohemorrhagic *Escherichia coli* (EHEC) producing Shiga toxin is the most common cause of HUS (typical HUS), accounting for 90% of pediatric cases. However, some cases are associated with inherent dysregulation of the complement system (atypical HUS, aHUS), commonly caused by mutations in components of the complement system, including factor H (CFH), factor I, factor B, or complement 3 [2]. In the

past, plasma therapy (plasma exchange or plasma infusion) was applied to ameliorate the dysregulation of complement activation, which is often insufficient to prevent permanent damage to the kidneys. Currently, monoclonal humanized anti-C5 antibodies, such as eculizumab, which block activation of the complement pathway, are the first-line treatment for aHUS with excellent renal outcomes [3]. However, C5 blockade is not always safe because the complement system plays a crucial role in the immune system, as indicated by the fatal outcome of meningococcal infection in patients who were treated with eculizumab, the first monoclonal humanized anti-C5 antibody approved for the treatment of aHUS [4]. Therefore, C5 blockade

Received: March 28, 2022; Revised: April 18, 2022; Accepted: April 19, 2022

### Correspondence to

Hee Gyung Kang

Department of Pediatrics, Seoul National University Children's Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea

E-mail: kanghg@snu.ac.kr

© 2022 Korean Society of Pediatric Nephrology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

is only indicated when dysregulated complement activation is involved in the pathophysiology of aHUS.

While *CFH* mutations are the most common cause of aHUS, especially in children [5,6], genes other than those involved in the complement system have also been implicated in aHUS. *DGKE*, encoding diacylglycerol (DAG) kinase epsilon (DGKE), is one such gene. Lemaire et al. [7] identified this gene using whole-exome sequencing of a patient with infantile aHUS. DGKE is found in the endothelium, platelets, and podocytes. In endothelial cells, arachidonic acid-containing DAG activate protein kinase C, promoting thrombosis, and DGKE normally inactivates DAG signaling [7]. Therefore, *DGKE* mutations result in a thrombogenic status, which is not related to complement pathway activation. *DGKE* mutations are known to cause steroid-resistant nephrotic syndrome or membranoproliferative glomerulonephritis [8]. In Republic of Korea, an aHUS case caused by a *DGKE* mutation has been reported previously [6], but the details of the clinical course are not well documented.


Here, we report the second case of aHUS caused by *DGKE* mutations in Republic of Korea.

## Case report


An 11-month-old male patient presented to a local pediatric clinic with a fever. Antibiotics were prescribed for the presumptive diagnosis of acute pharyngitis. A few days later, he developed diarrhea followed by vomiting and hematuria and was transferred to our institution. At our hospital, he had hypertension with a systolic blood pressure above 140 mmHg; he looked acutely ill and anemic. His tongue and lips were dehydrated, and he was edematous, especially in his extremities and eyelids. Laboratory workup showed anemia (hemoglobin [Hb], 6.3 mg/dL), thrombocytopenia (79,000/ $\mu$ L), high blood urea nitrogen (94 mg/dL), high creatinine (1.99 mg/dL), high lactate dehydrogenase (3,297 IU/L), hyperuricemia (14.2 mg/dL), hyperphosphatemia (7.2 mg/dL), high urine protein/creatinine ratio (UPCR; 16.14 g/g creatinine), and hematuria (50–99 red blood cells per high-power field [RBC/HPF]). His complement 3 level (112 mg/dL) and 4 level (18 mg/dL) were within normal limits. EHEC test result was negative and there was no stool Hb. On kidney ultrasonography, the parenchymal echogenicity of both kidneys increased without hydronephrosis. He had oliguria (80 mL/day, 7.8 mL/kg/day); thus, hemodialysis was administered for 1 day. Amlodipine, allopurinol, and calcium carbonate were prescribed for hypertension, hyperuricemia, and hyperphos-

phatemia, respectively. There was no laboratory evidence of EHEC infection, but the presumptive diagnosis was typical HUS because he had prodromal diarrhea. After seven days, almost all laboratory results improved with conservative management, similar to typical HUS. However, he was very young and did not have a history of raw food intake that could have caused EHEC infection. Therefore, the patient was discharged with a warning of recurrence and suspected aHUS. When he was 26-month-old, 15 months after the first episode, he had a fever of up to 39°C and melena. The fever subsided after 2 days, but he looked pale after 4 days, so he visited a local pediatric clinic. Hematuria, proteinuria, and anemia (Hb, 9.8 mg/dL) were found; therefore, he was transferred to our institution. In laboratory workup, mild anemia (Hb, 9.4 mg/dL) and mild creatinine elevation (0.42 mg/dL, baseline 0.35 mg/dL) were noted along with elevated plasma Hb (14.6 mg/dL) and lactate dehydrogenase (585 IU/L), suggesting hemolysis. Hematuria (>100 RBC/HPF) and proteinuria (UPCR, 5.60 g/g creatinine) were evaluated by urine analysis. Both stool polymerase chain reaction and culture were negative for EHEC. After admission, the patient's general condition and laboratory abnormalities improved without treatment for several days. Suspecting an aHUS relapse, a kidney biopsy was performed. The glomeruli were mildly increased in size and had focal mild hypercellular endothelial cells and tram-track appearance. Two global sclerotic glomeruli were noted among the 57 glomeruli. Slight focal infiltration of mononuclear cells was observed in the tubules. Diffuse thickened glomerular basement membrane, slight focal effacement of the foot process, subendothelial widening and mesangial interposition were observed by electron microscopy. In immunofluorescence staining, C3 and Lambda were reported as +/-, and IgM and C4d were reported as positive in the glomerular capillary loops and peritubular capillaries (Fig. 1). Therefore, the pathological findings were consistent with chronic TMA. The TMA gene panel revealed a homozygous nonsense mutation (c.1498C>T in exon11 (p.Arg500\*)) in *DGKE*. This gene panel covers 25 genes associated with TTP and HUS (*ADAMTS13*, *C1S*, *C2*, *C3*, *C5*, *C8A*, *C9*, *CD55*, *CD59*, *CFB*, *CFD*, *CFH*, *CFHR5*, *CFI*, *CR2*, *DGKE*, *F12*, *INF2*, *MASP1*, *MASP2*, *MMACHC*, *MMUT*, *PLG*, *THBD*, *WT1*).

Proteinuria was monitored during follow-up. When he was 31-month-old, his proteinuria increased to 1.17; therefore, enalapril was prescribed. After 2 weeks, proteinuria disappeared and he did not recur despite discontinuation of medications. At the age of 40 months, 29 months after the first episode, he experienced a third episode of aHUS along with a fever of up



**Fig. 1.** Pathologic findings. (A) Electron microscopy image. Diffuse thickened glomerular basement membrane and focal slight effacement of foot process were marked with red arrows. (B) Electron microscopy image. Subendothelial widening and mesangial interposition were marked with blue circle. (C) Periodic acid-Schiff staining image (×500). Endothelial cells were mildly hypercellular in the glomerulus and glomerular size was mildly increased (marked with black arrow). Some glomerulus showed tram-track appearance (marked with green arrowheads).



**Fig. 2.** Laboratory data. Fever events are annotated with red arrows. Hb, hemoglobin; UPCR, urine protein/creatinine ratio.

to 40°C and hematuria. Spontaneous remission was achieved within 1 month without medication. At the last follow-up at the age of 46 months, his blood pressure and laboratory findings were unremarkable, without proteinuria. Hb and UPCR levels during follow-up are displayed in Fig. 2.

**Discussion**

This is a case of recurrent HUS that showed spontaneous remission with supportive care. Because of the infantile-onset and relapse history, aHUS was suspected, and a *DGKE* muta-

tion was identified by a genetic test. The homozygous nonsense mutation of this patient (c.1498C>T in exon11 (p.Arg500\*)) has not been reported before. However, as it is a truncating mutation, the mutation is considered as pathogenic in this patient. Similar to previous reports on *DGKE* mutations, our case presented at a very early onset (median age <1 year) with aHUS with a self-limiting disease course [9,10]. His initial presentation was accompanied by diarrhea; therefore, typical HUS was suspected at first. However, aHUS is often triggered by infection, and the first episode in our case was triggered by gastrointestinal infection.

In general, HUS in young children is typically followed by bloody diarrhea due to EHEC infection. Typically, they have a history of ingesting raw or undercooked food. Otherwise, aHUS should be suspected, especially in very young infants. Unlike typical HUS, aHUS does not spontaneously remit and often relapses. Since it can be fatal, aggressive management is necessary, previously with plasma and now with C5 inhibitors, if aHUS is associated with complement dysregulation. The *CFH* mutation was first suspected in a case of very young aHUS. For aHUS with a *CFH* mutation, C3 levels often decrease, and approximately 60% to 70% of patients lose renal function if not properly managed [11]. However, our patient had normal C3 levels and a self-remitting course, which was not consistent with aHUS associated with complement dysregulation. In such cases, a *DGKE* defect must be suspected. Currently, correct genetic diagnosis is more important because of the availability of C5 inhibitors, the treatment of choice for complement-related aHUS.

Eculizumab, the currently available C5 inhibitor, is an antibody targeting the complement pathway; it is unrelated to the *DGKE* mutation, which is related to the coagulation pathway. There have been some case reports of *DGKE* mutation-associated aHUS in which eculizumab was effective [12]. However, these cases might have recovered even without eculizumab, since *DGKE*-associated aHUS is usually self-remitting. Eculizumab has been proven to be relatively safe and very effective for aHUS, but it is regularly administered to prevent relapse of aHUS once indicated. Therefore, even when aHUS is suspected, causes other than complement system dysregulation must be considered before deciding to administer C5 inhibitors. Other than *DGKE* mutations, secondary causes of aHUS include medication, malignancy, infection, autoimmune diseases, and genetic causes, such as cobalamin C defect or G6PD deficiency.

Despite the self-remitting course of aHUS caused by *DGKE* defects, the long-term outcome of *DGKE* defects is not favorable. Chronic kidney disease stages 4 and 5 are common in patients with *DGKE* mutation [7]. Until the last follow-up, our patient showed third relapse. Chronic relapse of aHUS or development of membranoproliferative glomerulonephritis and/or steroid-resistant nephrotic syndrome might occur in this patient in the future. Therefore, careful long-term follow-up was indicated in this case.

HUS in infants is not common, mandating the suspicion of aHUS. While *CFH* or other complement-related aHUS is more prevalent, *DGKE* mutations need to be suspected in cases with

normal complement levels and spontaneously recovering courses. Although aHUS related to *DGKE* may recur, a C5 inhibitor is not indicated. However, close follow-up is necessary, because other glomerulopathies may have occurred in this case.

## Ethical statements

This study was approved by the Institutional Review Board of Seoul National University Hospital (No. H-2011-048-1171). Informed consent from patient was obtained.

## Conflicts of interest

No potential conflict of interest relevant to this article was reported.

## Funding

This study was supported by a National Research Foundation of Korea (NRF) grant (No. 2020R1A2C1100974) funded by the Ministry of Science and ICT (MSIT), Government of the Republic of Korea.

## Author contributions

Conceptualization: BSS, YHA, HGK

Data curation: BSS

Formal analysis: BSS

Funding acquisition: YHA, HGK

Investigation: BSS

Methodology: BSS

Project administration: HGK

Visualization: BSS

Writing-original draft: BSS

Writing-review & editing: HGK

All authors read and approved the final manuscript.

## References

- Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. *Pediatr Nephrol* 2008;23:1957-72.
- Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. *Pediatr Nephrol*

- 2012;27:1283-91.
3. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol* 2016;31:15-39.
  4. McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. *MMWR Morb Mortal Wkly Rep* 2017;66:734-7.
  5. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated? *Hematology Am Soc Hematol Educ Program* 2012;2012:617-25.
  6. Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, et al. Atypical hemolytic uremic syndrome: Korean pediatric series. *Pediatr Int* 2015;57:431-8.
  7. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in *DGKE* cause atypical hemolytic-uremic syndrome. *Nat Genet* 2013;45:531-6.
  8. Bezdicka M, Pavlicek P, Blahova K, Hacek J, Zieg J. Various phenotypes of disease associated with mutated *DGKE* gene. *Eur J Med Genet* 2020;63:103953.
  9. Azukaitis K, Simkova E, Majid MA, Galiano M, Benz K, Amann K, et al. The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase  $\epsilon$ . *J Am Soc Nephrol* 2017;28:3066-75.
  10. Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, et al. Characterization of a new *DGKE* intronic mutation in genetically unsolved cases of familial atypical hemolytic uremic syndrome. *Clin J Am Soc Nephrol* 2015;10:1011-9.
  11. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med* 2009;361:1676-87.
  12. Husain D, Barron B, Barron AG, Sandokji I, Marsenic O, Warejko JK. Atypical hemolytic uremic syndrome due to *DGKE* mutation and response to eculizumab: lessons for the clinical nephrologist. *J Nephrol* 2021;34:1331-5.